Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: An ongoing phase I trial.

Functionalized liposomes for targeted breast cancer drug delivery

“…A phase I clinical trial for the first cisplatin-encapsulating liposomal formulation with a sPLA 2 -trigger, LiPlaCis®, was performed in advanced and/or refractory solid tumors including prostate, skin, and metastatic breast cancer (NCT01861496). In 2009 trials were halted due to safety issues requiring reformulation [ 353 ], after which the efficacy, dosage, and tolerability of LiPlaCis® continued to be assessed pre-clinically and in phase I/II clinical trials in advanced solid tumors such as head and neck, skin, colorectal, gastric, and breast cancers [ 214 , [354] , [355] , [356] ]. Østrem et al developed a liposomal delivery system optimized for sPLA 2 -triggered drug release by adjusting the fluidity and cholesterol level in the liposomes ( Fig.…”